This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sequoia, J. S.P. Articles by Albanes, D. Search for Related Content PubMed PubMed Citation Articles by Sequoia, J. S.P. Articles by Albanes, D.

A Prospective Investigation of Height and Prostate Cancer Risk

¹ Nutritional Epidemiology Branch and ² Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland; ³ Department of Epidemiology and Public Health, The Queen's University of Belfast, Belfast, United Kingdom; and ⁴ Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

Requests for reprints: Demetrius Albanes, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 6120 Executive Boulevard, EPS-3044, Bethesda, MD 20892. E-mail: daa{at}nih.gov

Greater adult height, which reflects a combination of early nutrition, exposure to androgens, growth hormones, and other factors during growth and development, as well as heredity, has been associated with increased prostate cancer risk in several observational studies, but findings have been inconsistent. We examined this relationship in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort. At baseline, 29,119 Finnish male smokers 50 to 69 years old had height and weight measured by trained personnel, provided information on demographic, smoking, medical, and other characteristics, and completed an extensive diet history questionnaire. A total of 1,346 incident prostate cancer cases were identified during a follow-up period of up to 17.4 years (median, 14.1 years). In age-adjusted Cox proportional hazards models, the hazard ratios and 95% confidence intervals for prostate cancer according to increasing quintiles of height [168, 169-171, 172-175, 176-178, and >178 cm] were 1.00 (reference), 1.11 (0.93-1.32), 1.11 (0.95-1.31), 1.30 (1.01-1.55), and 1.14 (0.96-1.35); P_trend = 0.04. In analyses stratified by disease stage (available for 916 cases), a strong dose-response relationship was observed between greater height and advanced, but not earlier-stage, disease [tumor-node-metastasis stage III-IV, hazard ratio and 95% confidence interval for increasing quintiles of height: 1.77 (1.18-2.65), 1.82 (1.25-2.65), 1.93 (1.29-2.90), and 2.02 (1.37-2.97); P_trend = 0.0008, P_interaction = 0.002]. Our study provides additional evidence that increased height is a risk factor for prostate cancer and suggests that taller men are particularly susceptible to advanced disease. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2174–8)

This article has been cited by other articles:

				Y. Minami, T. Tochigi, S. Kawamura, H. Tateno, S. Hoshi, Y. Nishino, and M. Kuwahara Height, Urban-born and Prostate Cancer Risk in Japanese Men Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 205 - 213. [Abstract] [Full Text] [PDF]